Market Trends of Post Operative Pain Management Industry
The Non-steroidal Anti-inflammatory Drugs (NSAIDs) Segment is Expected to Hold a Significant Share of the Market
The non-steroidal anti-inflammatory drugs (NSAIDs) segment is expected to hold a significant market share by drug class. Non-steroidal anti-inflammatory drugs (NSAIDs) are widely used to relieve pain, reduce inflammation, and bring down high body temperatures.
The major factors fueling the segment's growth are the implementation of strategic initiatives by the market players, the growing demand for NSAIDs owing to their advantages over other drugs, and the increasing number of surgical procedures. For instance, in March 2022, Health Canada issued a Notice of Compliance (NOC) to commercialize Heron Therapeutics' ZYNRELEF (bupivacaine, which is an amide local anesthetic, and meloxicam, which is a non-steroidal anti-inflammatory drug (NSAID) extended-release solution) for instillation into the surgical wound for post-operative analgesia after a bunionectomy, open inguinal herniorrhaphy, and total knee arthroplasty surgical procedures.
In March 2024, Eyenovia, in collaboration with its Taiwan-based partner, Formosa Pharmaceuticals, disclosed the FDA's approval of its clobetasol propionate 0.05% eye drops. These drops are meant to treat post-operative inflammation and pain following eye surgery.
Thus, the segment is expected to grow significantly over the forecast period due to the various strategic activities by the key players and the rise in acceptance of NSAIDs for post-operative pain management.
North America is Expected to Hold a Significant Share in the Market Over the Forecast Period
The United States is expected to hold a significant share of the market in North America. The major factors bolstering the market's growth are the growing number of surgical procedures, the surge in awareness regarding post-operative pain management drugs, the increasing number of product approvals, and the rising focus on palliative care.
The increase in the number of surgeries in the country is expected to propel the growth of the market. For instance, Cedars-Sinai data updated in January 2022 showed that coronary artery bypass graft surgery (CABG), also known as coronary artery bypass or bypass surgery, was the most common type of heart surgery. More than 300,000 people in the United States have successful bypass surgery each year. Such statistics are likely to increase the demand for post-operative pain management medications within the country, thereby boosting the market's growth.
Several guidelines and recommendations have been put forward by the healthcare authorities in the region, which is contributing to market growth. For instance, in March 2024, the American Academy of Orthopaedic Surgeons released updated guidelines for the treatment of hip osteoarthritis, which mentioned that pharmacologically managing hip osteoarthritis (OA) often involves the moderate recommendation of intra-articular corticosteroids. Additionally, intra-articular corticosteroids improve short-term function and reduce pain in patients with symptomatic hip OA.
Thus, owing to the above-mentioned factors, the market is expected to witness significant growth over the forecast period.
